Market Cap
$11.3B
TECH
BIO-TECHNE Corp
$72.42 ▲ +0.02%
Prev close $72.40Market cap$11.3B
ConsensusSell
12-mo target$70.50 (-2.6%)
▼ Bearish
Analyst conviction 3/10
High Impact Filing (7/10)36 New Institutional Positions14 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TECH right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Hold (32%)
Inst. Holders
50 funds
Inst. Value
$8.7B
Inst. Activity
36 buys / 14 sells
Social Sentiment
53° Neutral
SEC Reports
4
Congressional
2 trades
Price chart 30d +0.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 Insider
HIGGINS JOHN L surrendered for taxes 5,562 shares
Director @ $72.51 ($403.3K)
Sep 28, 2026 Insider
HIGGINS JOHN L acquired via exercise 15,940 shares
Director
Sep 23, 2026 m_and_a
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a
Sep 22, 2026 Insider
Aug 12, 2026 SEC BAUMGARTNER ROBERT V acquired via exercise 15,940 shares
Director
Bio-Techne reported Q4 FY2026 adjusted EPS of $0.52, a 2.1% beat vs $0.52 consensus, on revenue of $321.2M (1% reported
PRESS-RELEASE — Impact 4/10
Bio-Techne reported Q4 FY2026 results with organic revenue growth of 3% (reported +1% to $321.2M), GAAP EPS of $0.35 vs
8-K — Impact 7/10
Bio-Techne (TECH) filed a preliminary proxy statement (PREM14A) for a special shareholder meeting to vote on its acquisi
PREM14A — Impact 7/10
Jun 30, 2026 Inst.
FMR LLC — ADD
12,794,784 shares ($904.0M)
Analyst ratings buy % -59.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
32% rate it Buy or better · 22 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 13, 2026 | Wells Fargo | DOWNGRADE | Equal-Weight | 54% |
| Jul 9, 2026 | RBC Capital | DOWNGRADE | Sector Perform | 55% |
| Jun 30, 2026 | TD Cowen | DOWNGRADE | Hold | 56% |
| Jun 30, 2026 | Benchmark | DOWNGRADE | Hold | 54% |
| Jun 29, 2026 | Citigroup | DOWNGRADE | Neutral | 55% |
| Jun 26, 2026 | Stephens & Co. | DOWNGRADE | Equal-Weight | 54% |
| Jun 26, 2026 | William Blair | DOWNGRADE | Market Perform | 51% |
| Jun 26, 2026 | Baird | MAINTAIN | Neutral | 54% |
| Jun 11, 2026 | Piper Sandler | INITIATE | Neutral | 54% |
| May 7, 2026 | Citigroup | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 4 | 15 | 0 | 0 | 32% | |
| Aug 1, 2026 | 3 | 6 | 13 | 0 | 0 | 41% | |
| Jul 1, 2026 | 3 | 7 | 13 | 0 | 0 | 43% | |
| Jun 1, 2026 | 7 | 9 | 5 | 1 | 0 | 73% | |
| May 1, 2026 | 7 | 10 | 6 | 0 | 0 | 74% | |
| Apr 1, 2026 | 7 | 10 | 6 | 0 | 0 | 74% | |
| Mar 1, 2026 | 7 | 10 | 6 | 0 | 0 | 74% | |
| Feb 1, 2026 | 7 | 11 | 5 | 0 | 0 | 78% |
Price targets
Where 10 covering analysts think TECH trades over the next 12 months.
$70.50 -2.6% upside Hold
Current$72.42 Low$50.00 Median$73.00 High$73.00 10 analysts
$50.00$73.00
Analyst rating Hold· 2.8/5 as of Oct 2, 2026
Social media sentiment mood +13.6%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
53°
Neutral
BearishNeutralBullish
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 6.5/10.
NEUTRALPRESS-RELEASE4/10
Bio-Techne reported Q4 FY2026 adjusted EPS of $0.52, a 2.1% beat vs $0.52 consensus, on revenue of $
Aug 12, 2026
BULLISH8-K7/10
Bio-Techne reported Q4 FY2026 results with organic revenue growth of 3% (reported +1% to $321.2M), G
Aug 12, 2026
BULLISHPREM14A7/10
Bio-Techne (TECH) filed a preliminary proxy statement (PREM14A) for a special shareholder meeting to
Aug 11, 2026
BULLISHDEFA14A8/10
Bio-Techne has entered into a definitive agreement to be acquired by Merck KGaA for $73.00 per share
Jun 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 23, 2026
m_and_a
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents an
Sep 7, 2026
dark_pool
Dark Pool: TECH — 1.6M shares, 24,487 trades
Week starting 2026-09-07. Total ATS volume: 1,586,937 shares across 24,487 trades.
Aug 31, 2026
dark_pool
Dark Pool: TECH — 1.9M shares, 31,790 trades
Week starting 2026-08-31. Total ATS volume: 1,907,109 shares across 31,790 trades.
Aug 27, 2026
short_volume
Short Volume: TECH — 66.7% short (0.4M / 0.6M)
Short: 381,599 | Exempt: 411 | TRF Vol: 571,920 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
Aug 24, 2026
dark_pool
Dark Pool: TECH — 1.6M shares, 26,954 trades
Week starting 2026-08-24. Total ATS volume: 1,615,929 shares across 26,954 trades.
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.43 | $0.42–$0.44 | 1.9% | -0.1% | 1↑ 0↓ | $0.3B | 3 |
| Next Q | $0.47 | $0.46–$0.47 | 1.3% | -1.8% | 1↑ 0↓ | $0.3B | 3 |
| Current FY | $2.02 | $1.82–$2.11 | 4.5% | -0.1% | 2↑ 0↓ | $1.3B | 11 |
| Next FY | $2.31 | $2.03–$2.60 | 14.7% | +0.3% | 3↑ 0↓ | $1.4B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.428 | — |
| 7d ago | $0.428 | -0.001 |
| 30d ago | $0.428 | -0.001 |
| 60d ago | $0.439 | -0.011 |
| 90d ago | $0.441 | -0.013 |
Institutional ownership
Which big funds own TECH (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $8.7B total value (123,978,976 shares) as of 2026-Q2. Top holders: BlackRock,, FMR, VANGUARD. Net buying activity: 36 institutions added/increased vs 14 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 14,025,816 | $990.9M | 11.4% | — |
| FMR LLC | 12,794,784 | $904.0M | 10.4% | ADD +62.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 10,218,558 | $721.9M | 8.3% | — |
| GOLDMAN SACHS GROUP INC | 7,343,324 | $518.8M | 5.9% | DOUBLED +277.8% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,506,360 | $459.7M | 5.3% | — |
| MORGAN STANLEY | 6,374,717 | $450.4M | 5.2% | TRIM -25.3% |
| STATE STREET CORP | 5,980,370 | $422.5M | 4.8% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 5,351,464 | $377.5M | 4.3% | — |
| Invesco Ltd. | 4,986,424 | $352.3M | 4.0% | — |
| Neuberger Berman Group LLC | 2,844,692 | $201.0M | 2.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | ADD | 7,899,928 | 12,794,784 | +62.0% | $904.0M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 1,943,534 | 7,343,324 | +277.8% | $518.8M |
| MORGAN STANLEY | TRIM | 8,532,873 | 6,374,717 | -25.3% | $450.4M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | TRIM | 3,733,248 | 2,746,462 | -26.4% | $194.0M |
| JPMORGAN CHASE & CO | ADD | 1,025,105 | 1,862,805 | +81.7% | $132.6M |
| Amundi | DOUBLED | 72,315 | 1,827,241 | +2426.8% | $129.1M |
| MAVERICK CAPITAL LTD | TRIM | 4,739,721 | 1,535,610 | -67.6% | $108.5M |
| NORGES BANK | NEW | — | 1,413,639 | — | $99.9M |
| Bank of New York Mellon Corp | TRIM | 1,759,119 | 1,278,196 | -27.3% | $90.3M |
| MILLENNIUM MANAGEMENT LLC | NEW | — | 989,033 | — | $69.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | HIGGINS JOHN L | Director | TAX W/H | 5,562 | $72.51 | $403.3K |
| Sep 28, 2026 | HIGGINS JOHN L | Director | EXERCISE | 15,940 | — | — |
| Sep 22, 2026 | BAUMGARTNER ROBERT V | Director | EXERCISE | 15,940 | — | — |
| Sep 22, 2026 | BAUMGARTNER ROBERT V | Director | TAX W/H | 5,559 | $72.55 | $403.3K |
| Aug 17, 2026 | Crouse Steven C. | President - Diag & Spatial Bi | AWARD | 8,702 | — | — |
| Aug 17, 2026 | Crouse Steven C. | President - Diag & Spatial Bi | AWARD | 14,140 | — | — |
| Aug 17, 2026 | Hippel James | CFO | AWARD | 22,438 | — | — |
| Aug 17, 2026 | Hippel James | CFO | AWARD | 36,459 | — | — |
| Aug 17, 2026 | Kelderman Kim | Chief Executive Officer | AWARD | 57,590 | — | — |
| Aug 17, 2026 | Kelderman Kim | Chief Executive Officer | AWARD | 93,582 | — | — |
Congressional trades
TECH trades disclosed by members of Congress, with disclosure delay.
1 members · 0 buys / 2 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | April McClain Delaney | D | HOUSE | SELL | $1,001 - $15,000 | Bio-Techne Corp | May 7, 2026(30d) |
| Feb 24, 2026 | April McClain Delaney | D | HOUSE | SELL | $1,001 - $15,000 | Bio-Techne Corp | Mar 11, 2026(16d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TECH.
Shares short
6,627,623
Settlement Sep 15, 2026
Change vs prior
+12.5%
Semi-monthly cycle
Days to cover
2.7
At avg daily volume
Of shares outstanding
≈4.2%
Estimate — not % of float
All TECH filing & press-release reports (4)
- PRESS-RELEASE reportAug 12, 2026
- 8-K reportAug 12, 2026
- PREM14A reportAug 11, 2026
- DEFA14A reportJun 26, 2026